- Dana-Farber researchers report in the New England Journal of Medicine that ibrutinib, a newly approved drug for Waldenström's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients surviving for two years.
Tags: TargetedTherapy, TranslationalResearch, Lymphoma
- Young adults with cancer often face very different challenges than those who were diagnosed as children or older adults.
- Scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center have identified a protein critical to both normal brain development and, in many cases, the development of medulloblastoma, a fast-growing brain tumor that usually strikes children under 10. According to a report in the journal Developmental Cell, halving the level of the protein Eya1 in mice prone to develop medulloblastoma dramatically reduced the animals' risk of dying from the disease.
Tags: ChildhoodCancer, BrainTumors
- A new iPhone app launched by Apple today will provide physician researchers with instant data from breast cancer survivors with a goal of providing patients improved post-treatment quality of life.
Tags: BreastCancer, Survivorship
- Dana-Farber is one of 379 employers and employer organizations that signed on to an amicus curiae brief filed by Morgan Lewis in the United States Supreme Court in support of a single uniform law for same sex marriage.
- Websites that market personalized cancer care services often overemphasize their purported benefits and downplay their limitations, and many sites offer genetic tests whose value for guiding cancer treatment has not been shown to be clinically useful, according to a new study from Dana-Farber Cancer Institute.
Tags: Genomics, Genetics
- With March marking Colorectal Cancer Awareness Month, Dr. Jeffrey Meyerhardt answers some key questions about the disease.
- New patients with cancer can now make an appointment to see an oncologist as soon as the following day at Dana-Farber/Brigham and Women's Cancer Center.
- A new laboratory test predicts which of several cancer drugs will work best against a patient's tumor, and could become a powerful precision medicine tool for individualizing cancer therapy.
Showing 21-30 of 598 items